p38α mitogen-activated protein kinase inhibitors, a patent review (2005 – 2011)

Author： Fischer Stefan Koeberle Solveigh C Laufer Stefan A

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.21, Iss.12, 2011-12, pp. : 1843-1866

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Structure-Activity Relationships of p38 Mitogen-Activated Protein Kinase Inhibitors

Mini Reviews in Medicinal Chemistry, Vol. 5, Iss. 9, 2005-01 ,pp. : 857-868

Bentham Science Publishers

Access to resources Recommend Favorite

p38 Mitogen-Activated Protein Kinase Inhibitors: A Review on Pharmacophore Mapping and QSAR Studies

Current Topics in Medicinal Chemistry, Vol. 13, Iss. 9, 2013-05 ,pp. : 1015-1035

Bentham Science Publishers

Access to resources Recommend Favorite

Therapeutic potential of inhaled p38 mitogen-activated protein kinase inhibitors for inflammatory pulmonary diseases

By Chopra Puneet Kanoje Vijay Semwal Arvind Ray Abhijit

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 10, 2008-10 ,pp. : 1411-1425

Informa Healthcare

Access to resources Recommend Favorite

p38 Mitogen-Activated Protein Kinase (MAPK) in Rheumatoid Arthritis

Mini Reviews in Medicinal Chemistry, Vol. 6, Iss. 8, 2006-08 ,pp. : 867-874

Bentham Science Publishers

Access to resources Recommend Favorite

Immunosuppressant rapamycin inhibits protein kinase C and p38 mitogen-activated protein kinase leading to the inhibition of chondrogenesis

By Oh C.-D. Kim S.-J. Ju J.-W. Song W.K. Kim J.-H. Yoo Y.J. Chun J.-S.

European Journal of Pharmacology, Vol. 427, Iss. 3, 2001-09 ,pp. : 175-185

Elsevier

Access to resources Recommend Favorite